Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terbogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 20/20 | 0.74 |
| ▸ | TBXAS1 known ✓ | P24557 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbogrel SCHEMBL27132959 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL42848 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL2924118 | 1.00 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL15413064 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL42849 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537036 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL31680499 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL15413066 | 0.82 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL29383187 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537032 | 0.82 | TBXA2R (0.75) | TBXA2RTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-11-11 | — | — | US | disclosed |
| EP-2227560-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071661-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-06-11 | — | — | WO | disclosed |
| EP-1863534-A1 | COMPOSITION COMPRISING A COMBINED THROMBOXANE RECEPTOR ANTAGONIST AND THROMBOXANE SYNTHASE INHIBITOR AND A COX-2 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100213-A1 | COMPOSITION COMPRISING A COMBINED THROMBOXANE RECEPTOR ANTAGONIST AND THROMBOXANE SYNTHASE INHIBITOR AND A COX-2 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217431-A1 | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217431-A1 | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor | TBXA2R, PTGES2, PTGER2 | TBXA2R 1/4885TBXAS1 8/4885 |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | TBXAS1, TBXA2R, HPGDS | TBXA2R 2/4885TBXAS1 1/4885 |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | TBXAS1, TBXA2R, HPGDS | TBXA2R 2/4885TBXAS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.